Dublin, Nov. 09, 2020 (GLOBE NEWSWIRE) — The “North America Microtome Market to 2027 – Country Analysis and Forecasts by Product (Microtome Instruments, Microtome Accessories); Technology (Manual Microtomes, Semi-automated Microtomes, Fully Automated Microtomes); End User (Hospitals, Clinical Laboratories, Other End Users)” report has been added to ResearchAndMarkets.com’s offering.
The North America microtome market is expected to reach US$ 94,198.6 thousand in 2027 from US$ 59,961.2 thousand in 2019. The market is expected to grow with a CAGR of 6.0% from 2020-2027.
The growth of the North America microtome market is estimated to grow due to critical factors such as the rising prevalence of cancer, and increasing adoption of digital pathology is expected to propel the growth of the market. Yet, the lack of skilled professionals is one of the major factors hindering the market growth.
Digital diagnosis has become a crucial aspect of the lab for surgical pathology. Nowadays, formalin-fixed paraffin-embedded (FFPE) slides are digitally scanned into high-resolution digital images. These are then viewed, analyzed, and shared with other pathologists for better diagnostic results.
With the global figure of new cancer cases anticipated to rise, pathology laboratories are studying for ways to meet the increased demand for their services. This has directed to the increasing adoption of digital pathology that allows laboratories to work more efficiently. Digitalization in pathology labs has been increasing witnessed in the US and other developed countries over the last few years.
Many countries have started adopting the digital pathology framework, which in turn offering lucrative opportunities for the growth of the market. For instance, Sectra received a 510(k) approval by the US FDA. The clearance implements for the Sectra Digital Pathology Module. Permission allows US healthcare providers to use Sectra’s digital pathology solution for primary diagnostics. The purpose of digital pathology technology is expected to help pathologists in diagnosing clinical histology cases digitally to enhance laboratory efficiency and quality. Thus, increasing the adoption of digital pathology drives the growth of the North America microtome market in the forecast period.
North America microtome market, based on the product, was segmented into microtome instrument and microtome accessories. In 2019, the microtome instrument segment held the highest share of the market. Furthermore, the corresponding segment is expected to grow at the fastest rate during the upcoming years.
Based on technology, the North America microtome market was segmented into fully automated microtomes, semi-automated microtomes, and manual microtomes. In 2019, a fully automated microtomes segment held the largest share of the market. Further, the same segment is anticipated to grow at the fastest rate during the forecasted period.
Based on end user, the North America microtome market was segmented into clinical laboratories, hospital, and other end users (pharma biotech, academic research, agriculture). In 2019, the clinical laboratories segment held the largest share of the market. Besides, the same segment is expected to grow at the fastest rate during the coming year.
Key Topics Covered:
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
DUBLIN–(BUSINESS WIRE)–Nov 2, 2020–
The “Europe Microtome Market to 2027 – Country Analysis and Forecasts by Product (Microtome Instruments, Microtome Accessories); Technology (Manual Microtomes, Semi-automated Microtomes, Fully Automated Microtomes); End User (Hospitals, Clinical Laboratories, Other End Users)” report has been added to ResearchAndMarkets.com’s offering.
Europe microtome market is expected to reach US$ 58,738.7 thousand in 2027 from US$ 38,985.9 thousand in 2019. The market is predicted to grow with a CAGR of 5.4% from 2020-2027.
The growth of the Europe microtome market is estimated to grow due to critical factors such as the rising prevalence of cancer, and increasing adoption of digital pathology is expected to propel the growth of the market. Yet, the lack of skilled professionals is one of the major factors hindering the market growth.
Digital diagnosis has become a crucial aspect of the lab for surgical pathology. Nowadays, formalin-fixed paraffin-embedded (FFPE) slides are digitally scanned into high-resolution digital images. These are then viewed, analyzed, and shared with other pathologists for better diagnostic results. With the global number of new cancer cases expected to rise, pathology laboratories are looking for ways to meet the increased demand for their services.
This has directed to the increasing adoption of digital pathology that allows laboratories to work more efficiently. Digitalization in pathology labs has been increasing witnessed in the US and other developed countries over the last few years. Increasing technological advancements in digital pathology are further accelerating the growth of the market for microtomes. For instance, Tissue-Tek Auto Section automated microtome from Sakura Finetek offers the advantage of automation over manual microtomes.
Moreover, increasing the volume of routine tissue examinations is also increasing the demand for auto mated microtomes in the forecast period. To handle such a large sample size automated microtomes offer numerous benefits to pathologies such as high speed, improved efficiency, and reduces strain.
With the dawn of digitalization, the healthcare sector has undergone significant changes. Rising prevalence of chronic conditions is leading to clinical urgency, thereby increasing the adoption of digital pathology to improve existing inferior diagnostic methods. Clinical laboratories have been widely using microtome for diagnosis purposes. Thus, increasing the adoption of digital pathology drives the growth of the Europe microtome market in the forecast period.
Europe microtome market, based on the product, was segmented into microtome instrument and microtome accessories. In 2019, the microtome instrument segment held the highest share of the market. Furthermore, the corresponding segment is expected to grow at the fastest rate during the upcoming years.
Based on technology, the Europe microtome market was segmented into fully automated microtomes, semi-automated microtomes, and manual microtomes. In 2019, a fully automated microtomes segment held the largest share of the market. Further, the same segment is anticipated to grow at the fastest rate during the forecasted period.
Based on end user, the Europe microtome market was segmented into clinical laboratories, hospital, and other end users (pharma biotech, academic research, agriculture). In 2019, the clinical laboratories segment held the largest share of the market. Besides,
Back in 2014, then-California Atty. Gen. Kamala Harris imposed a strict condition on the affiliation between Hoag Memorial Hospital and St. Joseph Health System, a Catholic hospital group: For the most part, Hoag was to be exempt from Catholic church restrictions on women’s healthcare services.
Doctors at Newport Beach-based Hoag say that condition has been flagrantly breached by Providence Health, the successor to St. Joseph — and the violations are proliferating.
Since 2015 and up to the present day, a managed health plan controlled by Providence has been refusing to pay for contraceptives prescribed by Hoag OB/GYNs for their patients.
We would like to be tops in women’s healthcare, but how can we be if there are certain things we will never be able to provide, based on our association with Providence?
Jeffrey Illeck, an OB/GYN at Hoag Memorial Hospital
The health maintenance organization, Heritage Healthcare, has cited the Ethical and Religious Directives for Catholic Health Care Services as grounds for refusing payment, even though the 2014 agreement under which Harris approved the affiliation explicitly states that Hoag would not be bound by the so-called ERDs then or “in the future.”
Frustration among Hoag OB/GYNs has been rising.
Several members of Hoag’s professional staff filed a confidential complaint with Atty. Gen. Xavier Becerra’s office on Oct. 9.
The complaint asserts that “Providence has increasingly disallowed women’s health services when they involve any form of contraceptive care,” even when IUDs are prescribed for reasons other than birth control, such as heavy menstrual bleeding.
Providence also has refused to cover deliveries when they’re combined with sterilization procedures such as salpingectomies (the removal of one or both fallopian tubes), even though combining those procedures is the standard of care to avoid requiring a patient to undergo two rounds of anesthesia and recovery rather than one.
The complaint says that physicians’ staffs are spending many hours a day pursuing reimbursement claims for Heritage enrollees.
“We have seen IUD reimbursements, for example, pending for as long as two years, requiring multiple appeals and grievances on behalf of patients,” the complaint states. Billing staff “have never spent so much time trying to get reimbursements for IUDs. … In many cases, payment is never received.”
The Hoag doctors say that Providence established “an anonymous hotline for people to complain if they believed Hoag was committing so-called immoral procedures involving women’s reproductive health.” The hotline was connected to the Orange County bishop’s office, they say, adding: “We were never told of its existence.”
In sum, “Providence has established a history of broken trust in its relationship with us, with absolutely no end in sight,” says the complaint, which is not a public document but which I’ve reviewed.
Providence has refused to comment on any of these assertions.
Becerra has not responded to the complaint,
The fall surge has left nearly 50,000 people hospitalized across the US due to Covid-19, and experts say the strain healthcare systems are under could soon get worse.
Hospitalizations were on the rise in 47 states last month, according to the Covid Tracking Project, and a total of 47,502 people were hospitalized as of Sunday. The rates come alongside a surge of cases that made October a record setting month for coronavirus infections in the US.
The US recorded its highest number of new cases on Friday with a reported 99,321, the record for any nation in the world. And experts have said that the impacts will likely continue to get worse as colder months drive up infections.
“We’re right at the beginning of what looks like exponential growth in a lot of states,” Dr. Scott Gottlieb, former commissioner of the US Food and Drug Administration, said on CBS’s “Face the Nation” on Sunday. “This is very worrisome as we head into the winter.”
Gottlieb expects Thanksgiving to be an inflection point, and from there he said the hospital system is going to be facing pressure similar to the early spikes — when hospitals around the country were reaching capacity and healthcare workers were stretched thin.
Dr. Christopher Murray, director of the University of Washington’s Institute for Health Metrics and Evaluation, said hospitalizations are the best measure of how the nation is faring against the pandemic and are often an indicator of how the number of deaths will trend.
The seven-day average for new cases currently is more than 81,300 — higher than any other time in the pandemic. The surge has brought cases to more than 9.2 million in the US since the pandemic began, and 230,996 people have died, according to data from Johns Hopkins University.
Coronavirus accelerating in states
Covid-19 spread and hospitalizations have reached staggering levels across states.
This week, there were more new coronavirus cases in Kentucky than any other week since the pandemic began, Gov. Andy Beshear said in a statement Sunday.
“I know we’re tired, but if we do not get the spread of this disease under control, we risk a darker, more deadly period this winter than we ever experienced in the spring,” Beshear said.
Illinois is working to manage the virus by putting the entire state under resurgence mitigation measures, Gov. J.B. Pritzker and the Illinois Department of Public Health said Sunday. The state reported nearly 7,000 new cases on Sunday.
“As cases, hospitalizations and deaths are rising across our state, across the Midwest and across the nation, we have to act responsibly and collectively to protect
FORT LAUDERDALE, Fla. — When temperatures drop, so do green iguanas — from the trees. But evolution, it seems, could be robbing South Floridians of a tradition as common as checking the heat index on New Year’s Day.
Research shows that in recent years, several species of lizards have grown more tolerant of cold temperatures. It’s a discovery with big implications for Florida, where bouts of cool weather keep invasive iguanas contained to the southern regions of the state and helps keep populations under control.
It also could mean fewer images on social media and TV news of iguanas lying on their backs under trees, legs in the air, stunned until the warm sunshine gets their bodies moving again.
As recently as four years ago, most of South Florida’s most common species of lizards could tolerate temperatures between 46 and 52 degrees. Now, they hold up in temperatures as low as 44 degrees, according to a study done by a researcher at Washington University in St. Louis.
That means it’s possible that iguanas could expand their territory beyond their normal stomping grounds of Miami-Dade, Broward and Palm Beach counties.
“The potential is they could spread farther and disperse farther, so that’s why it’s interesting to Florida, specifically” said James Stroud, the research associate who conducted the study and did his doctoral work at Florida International University.
That’s bad news considering iguanas are invasive, propagate profusely and wreak havoc on homes, gardens, sidewalks, pool decks, seawalls, boats and anywhere else they eat and, well, poop. They’re so destructive, the state of Florida issued a call for homeowners to kill them. (It later clarified the statement, saying it’s best to call a professional to do the deed.)
Iguanas fall out of trees during cool weather because they’re cold-blooded and tropical. Low temperatures cause them to become sluggish and, in some cases, immobile. If it happens while they’re sleeping in trees, they often fall to the ground. They’re cold-stunned, not usually dead — they spring back into action once temperatures warm again if the fall from the tree doesn’t kill them.
It happened this past January, raining iguanas when temperatures in parts of South Florida fell to 39 degrees, the coldest air in about a decade. It also happened in January of 2018.
Stroud and his colleagues studied six lizard species common in South Florida — one that’s native (the American green anole), three Caribbean lizards that are not native (one each from Puerto Rico, Cuba and Hispaniola), the northeast tropical gecko, and the brown basilisk lizard.
Iguanas weren’t included because they were too big to fit into the refrigerator-like device used to study the chilled lizards. But Stroud said he believes the results apply to iguanas, too.
Blake Wilkins, co-owner of Hollywood-based Redline Iguana Removal, said the discovery doesn’t surprise him. While collecting iguanas during last January’s cold spell, he saw signs that iguanas might be warming up to the cold.
“I noticed a lot of them were actually in
Coronavirus hospitalizations are growing in 37 states as Fauci warns the world not ‘on the road’ to ending pandemic yet
- Covid-19 hospitalizations were growing by 5% or more, based on a weekly average, in 37 states as of Sunday, according to a CNBC analysis of data collected by the Covid Tracking Project.
- Alaska, Iowa, Kentucky, Montana, Nebraska, Oklahoma, South Dakota, Utah, Wisconsin and West Virginia all hit record highs in the average of hospitalizations.
- Covid-19 hospitalizations, like the so-called positivity rate and deaths, are a key measure because they help scientists gauge the pandemic’s severity.
Coronavirus hospitalizations are growing in a majority of U.S. states as Dr. Anthony Fauci, the nation’s leading infectious disease expert, warns that the world is not yet “on the road” to ending the pandemic.
Coronavirus hospitalizations, like the so-called positivity rate and deaths ,are a key measure because they help scientists gauge the pandemic’s severity.
Covid-19 hospitalizations were growing by 5% or more in 37 states as of Sunday, according to a CNBC analysis of data collected by the Covid Tracking Project, an increase from 36 states a week earlier. Figures are based on a weekly averages to smooth out daily reporting.
Alaska, Iowa, Kentucky, Montana, Nebraska, Oklahoma, South Dakota, Utah, Wisconsin and West Virginia all hit record highs in the average of hospitalizations, the Covid Tracking Project data shows. The District of Columbia and Hawaii are the only two places where hospitalizations are declining, according to the data.
In Texas, where hospitalizations are growing, 6.71% of beds across its hospitals have Covid-19 patients as of Sunday, according to state data. In Wisconsin, 10.9% of its beds have Covid-19 patients, state data shows.
“What’s concerning here is that it’s only mid-October and there is a long fall and winter,” said Dr. Isaac Bogoch, an infectious disease specialist and professor at the University of Toronto.
“We are clearly in the second wave in many parts of the Northern Hemisphere and we really need to have more control of this infection at the community level,” he said. “We know exactly what it’s like when health-care systems are spread beyond capacity. We saw that in New York City. We saw that in Houston. We saw that in many other parts of the United States.”
The increase in hospitalizations comes after U.S. cases have grown in recent weeks following a late-summer lull. Over the past seven days, the country has reported an average of about 56,000 new cases per day, up more than 13% compared with a week earlier, according to a CNBC analysis of Johns Hopkins University data. That remains lower than the roughly 70,000 new cases a day the U.S. was reporting earlier this year but is higher than the roughly 30,000 cases per day in early September and is increasing.
U.S. health officials and infectious disease experts have repeatedly warned that the outbreak could get worse as temperatures cool and people begin to head
The global hemoglobin testing market size is poised to grow by USD 612.82 million during 2020-2024, progressing at a CAGR of almost 8% throughout the forecast period, according to the latest report by Technavio. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment. The report also provides the market impact and new opportunities created due to the COVID-19 pandemic. Download a Free Sample of REPORT with COVID-19 Crisis and Recovery Analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201016005222/en/
Technavio has announced its latest market research report titled Global Hemoglobin Testing Market 2020-2024 (Graphic: Business Wire)
Globally, the prevalence of diabetes has significantly increased over the decades. This can be attributed to sedentary lifestyles, obesity, and lack of physical activity. The prevalence of diabetes is growing significantly in countries across the Middle East such as Iran, where around 24% of the people aged over 40 have diabetes. In the UAE, more than 16% of the total population aged 20-79 years had diabetes in 2019. The rising prevalence of diabetes has increased the demand for effective and advanced hemoglobin testing devices to monitor glucose levels, thereby driving the growth of the market.
Register for a free trial today and gain instant access to 17,000+ market research reports.
Technavio’s SUBSCRIPTION platform
The major hemoglobin testing market growth came from the healthcare centers segment in 2019. This is due to the increasing number of hospitals in developing countries and the growing trend of medical tourism.
North America was the largest market for hemoglobin testing in 2019, and the region will offer several growth opportunities to market vendors during the forecast period. This is attributed to the increasing prevalence of obesity and diabetes in the region.
The global hemoglobin testing market is fragmented. Abbott Laboratories, ACON Laboratories Inc., Bayer AG, Bio-Rad Laboratories Inc., Danaher Corp., Diazyme Laboratories Inc., EKF Diagnostics Holdings Plc, F. Hoffmann-La Roche Ltd., Siemens AG, and Thermo Fisher Scientific Inc. are some of the major market participants. To help clients improve their market position, this hemoglobin testing market forecast report provides a detailed analysis of the market leaders.
As the business impact of COVID-19 spreads, the global hemoglobin testing market 2020-2024 is expected to have neutral growth. As the pandemic spreads in some regions and plateaus in other regions, we revaluate the impact on businesses and update our report forecasts.
Read the full report here: https://www.technavio.com/report/hemoglobin-testing-market-industry-analysis
Growing preference for home care settings will be a Key Market Trend
Over the years, the demand for homecare blood testing devices has increased across the globe. This is because home care testing devices provide faster results and help patients better manage their disease. They also reduce the overall investigation time and the number of visits to hospitals outpatient department and diagnostic laboratories. This has encouraged vendors in the market to offer a wide range of diagnostics devices that are ideal for home use. For instance, PTS